eMIMSelite 앱 분석 (10월 9일)
eMIMSelite
- MIMS PTE. LTD.
- Apple App Store
- 무료
- 의료
MIMS Australia introduces eMIMSelite, a premium medicine reference subscription designed to support healthcare professionals in delivering high-quality patient care, even in offline environments.
eMIMSelite offers extensive, validated information on all registered medicines in Australia, along with specialised content including drug-disease contraindications, safe administration of IV injectables, sports medicine, and dental monographs.
Key features include:
Offline access ensuring uninterrupted use regardless of internet connectivity.
Advanced authentication and integration with organizational libraries.
Rapid search and retrieval of product information, consumer medicine information, product images, drug interactions, and PBS data.
MIMS Interaction Checker to identify:
a. Potentially harmful combinations of medicines
b. Medicines that may be unsuitable due to the patient’s allergy profile
c. Medicines that may be unsuitable due to a health condition
Easy access to need-to-know information on medicine and solution compatibility for safe administration of IV injectable medicines.
Access essential dental-specific medicine information such as effects on dental treatment, recommendations for dental patients, and more.
Identify potentially prohibited medications in and out of competition based on the World Anti Doping Agency (WADA) list.
Premium Tool, Specialized Curated Content
Disclaimer: eMIMSelite is strictly meant to be used by Healthcare Professionals – Doctors, Nurses, Pharmacists & Medical Students.
For more information: https://emims.plus/emimselite/
To access the platform: https://app.emims.plus/signup
For Support:
Email: subscriptions@mims.com.au
Phone: 1800 800 629
Available: Monday – Friday, 9:00 AM – 5:00 PM AEST
스토어 순위
스토어 순위는 Google과 Apple이 설정한 여러 매개변수를 기반으로 합니다.
모든 카테고리 ·
미국--
의료 ·
미국--
월평균 다운로드를 확인하려면 계정을 만드세요문의하기
eMIMSelite 순위 통계 추이
eMIMSelite의 Similarweb 사용량 순위 및 Apple App Store 순위
순위
데이터가 없습니다
주요 경쟁 앱 및 대체 앱
같은 스토어에서 동일한 사용자가 사용할 가능성이 높은 앱입니다.
10월 9, 2026